Pre-made Atoltivimab benchmark antibody ( Whole mAb, anti-Zaire Ebolavirus GP therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-038

Pre-Made Atoltivimab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Atoltivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus).

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-038-1mg 1mg 3090 Inquiry Inquiry

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Atoltivimab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP therapeutic antibody
INN Name Atoltivimab
TargetZaire Ebolavirus GP
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesRegeneron Pharmaceuticals
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedEbola virus infections
Development Techna